Alan Colman

CIK: 0001577873

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (83.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VNRX

VOLITIONRX LTD

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

VNRX
VOLITIONRX LTD
Jan 22, 2026
Award(A)
Direct
12K shares-
VNRX
VOLITIONRX LTD
Mar 1, 2025
Award(A)
Direct
14.8K shares-
VNRX
VOLITIONRX LTD
Jan 29, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
25K shares-
VNRX
VOLITIONRX LTD
Jan 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
25K shares-
VNRX
VOLITIONRX LTD
Dec 1, 2024
Award(A)
Direct
13K shares-
VNRX
VOLITIONRX LTD
Sep 1, 2024
Award(A)
Direct
13.8K shares-

		Type	Shares	Price		Ownership
Jan 22, 2026	VNRX VOLITIONRX LTD	Award(A)	12,000	-	$0	Direct
Mar 1, 2025	VNRX VOLITIONRX LTD	Award(A)	14,840	-	-	Direct
Jan 29, 2025	VNRX VOLITIONRX LTD	Disposition(D) Stock Option (Right to Buy)	25,000	-	-	Direct
Jan 29, 2025	VNRX VOLITIONRX LTD	Award(A) Stock Option (Right to Buy)	25,000	-	-	Direct
Dec 1, 2024	VNRX VOLITIONRX LTD	Award(A)	12,972	-	$0	Direct
Sep 1, 2024	VNRX VOLITIONRX LTD	Award(A)	13,757	-	$0	Direct

1-6 of 6 transactions

About Colman Alan

Colman Alan (SEC CIK 0001577873) files insider reports with the SEC as Director of VOLITIONRX LTD (VNRX).

Signal8 holds 5 ownership filings by Colman Alan, all Form 4s, filed between Sep 4, 2024 and Jan 23, 2026. Those filings report 6 transactions, from Sep 1, 2024 to Jan 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Colman Alan's filings is in HENDERSON, NV.

Recent filings by Colman Alan

Jan 22, 2026: Grant or award of VNRX shares (Form 4, code A).
Mar 1, 2025: Grant or award of VNRX shares (Form 4, code A).
Jan 29, 2025: Disposition to issuer transaction of VNRX derivative securities (Form 4, code D).
Jan 29, 2025: Grant or award of VNRX derivative securities (Form 4, code A).
Dec 1, 2024: Grant or award of VNRX shares (Form 4, code A).

Other insiders filing for VOLITIONRX LTD (VNRX)

Batchelor Ann-Louise, Group Chief Marketing Officer
Forterre Gael, Chief Commercial Officer
Rootsaert Rodney Gerard, Secretary
Micallef Jacob Vincent, Chief Scientific Officer
Plummer Nicholas, GC - Volition Diagnostics
Rubin Ethel, Director

How to read Form 4 transaction codes